TFIIS.h, a new target of p53, regulates transcription efficiency of pro-apoptotic bax gene

Jun-Ming Liao¹, Bo Cao¹, Jun Deng¹,², Xiang Zhou¹, Michael Strong³, Shelya Zeng¹, Jianping Xiong², Erik Flemington³ & Hua Lu¹

Tumor suppressor p53 transcriptionally regulates hundreds of genes involved in various cellular functions. However, the detailed mechanisms underlying the selection of p53 targets in response to different stresses are still elusive. Here, we identify TFIIS.h, a transcription elongation factor, as a new transcriptional target of p53, and also show that it can enhance the efficiency of transcription elongation of apoptosis-associated bax gene, but not cell cycle-associated p21 (CDKN1A) gene. TFIIS.h is revealed as a p53 target through microarray analysis of RNAs extracted from cells treated with or without inauhzin (INZ), a p53 activator, and further confirmed by RT-q-PCR, western blot, luciferase reporter, and ChIP assays. Interestingly, knocking down TFIIS.h impairs, but overexpressing TFIIS.h promotes, induction of bax, but not other p53 targets including p21, by p53 activation. In addition, overexpression of TFIIS.h induces cell death in a bax-dependent fashion. These findings reveal a mechanism by which p53 utilizes TFIIS.h to selectively promote the transcriptional elongation of the bax gene, upsurging cell death in response to severe DNA damage.

In response to various stresses, tumor suppressor p53 transcriptionally regulates the expression of hundreds of genes associated with several essential biochemical pathways, including cell cycle arrest, apoptosis, senescence, DNA repair, autophagy, and ferroptosis¹⁻⁴. Interestingly, these p53 responsive cellular effects are not induced simultaneously in response to different stresses, but rather are determined by the severity and duration of the cellular insults⁵⁻¹¹. For example, cell cycle arrest is often required for DNA repair, while apoptosis is usually the last choice of cells to avoid transformation⁵⁻¹²⁻¹⁴. It is therefore logical that DNA repair- and cell cycle-associated genes should be activated at the early stage, while the apoptosis-associated target genes should be induced at the later stage upon p53 activation. Thus, the kinetics of expression of p53 targets are tightly regulated and fine-tuned to maintain homoeostasis and prevent tumorigenesis. Although posttranslational modifications of p53 and the promoter strength of target genes are thought to be associated with the selection of p53 targets at the transcription initiation and post-translation level¹⁰,¹³,¹⁵⁻²², little is known about whether selection of p53 target genes is regulated at the transcription elongation level.

TFIIS is a transcription elongation factor that is required for RNA Pol II to pass through attenuated sites, thus promoting transcription elongation²³,²⁴. TFIIS has three family members, TFIIS.o, TFIIS.l, and TFIIS.h, which are encoded in humans by the TCEA1, TCEA2, and TCEA3 genes, respectively²⁵. TFIIS.o is widely expressed in human tissues and is considered a "general" form of TFIIS, whereas TFIIS.l is a testis-specific isoform²⁶. TFIIS.h was identified later on, and little is known about its specificity and functionality²⁷. Knockout of TFIIS.o in mice causes embryotic lethality²⁸, suggesting that efficient transcription elongation is vital for cellular functions. TFIIS.o also plays an oncogenic role in tumorigenesis, as knockdown of TFIIS.o suppresses proliferation and induces apoptosis in pancreatic, lung, and breast cancer cells²⁹. By contrast, TFIIS.h appears to act as a tumor suppressor in cancer cells, as overexpression of TFIIS.h inhibits, while knockdown of TFIIS.h promotes, growth of ovarian cancer cells²⁸. The opposite roles of TFIIS.o and TFIIS.h in cancers implicate that TFIIS.h might have different targets and act to selectively induce certain pools of genes in response to variable circumstances.

¹Department of Biochemistry & Molecular Biology and Cancer Center, Tulane University School of Medicine, 1430, Louisiana, LA 70112, USA. ²Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, PR China. ³Department of Pathology and Cancer Center, Tulane University School of Medicine, 1430, Louisiana, LA 70112, USA. Correspondence and requests for materials should be addressed to H.L. (email: hlu2@tulane.edu)
Accumulating evidence has shown that transcription elongation is not always efficient, and the RNA polymerase II (Pol II) complex could be stalled at various arrest sites with specific DNA sequences. It has also been reported that depletion of TFIIS.o causes transcription elongation arrest at sites with specific DNA sequences. Therefore, it is possible that genes with elongation arrest sites might need another layer of regulation to facilitate their expression. These studies suggest that selection of p53 targets might also be regulated at the transcription elongation level. In this study, by treating cells with Inauhzin (INZ), a small molecule discovered in our lab as a p53 activator through ribosomal stress and/or p53 acetylation, we found that TFIIS.h is a p53 target and plays a p53-dependent role in selective promotion of the transcription elongation of \textit{bax} gene, an apoptosis-associated target of p53, but not of \textit{p21}, a cell cycle-associated target, providing a new insight into a novel layer of regulation of p53 targets' expression at the transcriptional elongation level.

Results

TFIIS.h expression is induced by p53 activation. To identify novel p53 targets, we treated both HCT116 p53\(^{+/+}\) and HCT116 p53\(^{-/-}\) (without active p53) cells with or without INZ, a p53 activator identified by our lab. Microarray analysis of total RNAs extracted from these samples (triplicated) showed that TFIIS.h mRNA was induced by INZ only in HCT116 p53\(^{+/+}\), but not in HCT116 p53\(^{-/-}\) cells. Cells were treated with 4 μM INZ or DMSO as indicated and harvested for RT-q-PCR assay to confirm the results from microarray analysis. Data are presented as means ± S.D., n = 3. (C) Ectopic p53 induces TFIIS.h expression dose-dependently. H1299 cells transfected with indicated plasmids were harvested and subjected to RT-q-PCR assay. Data are presented as means ± S.D., n = 4. (D) TFIIS.h protein expression is induced by p53 activation in response to MG132 and doxorubicin (Dox). HCT116 cells were treated with indicated drugs and harvested for WB analysis to determine the endogenous TFIIS.h protein level.

p53 directly binds to TFIIS.h promoter. To determine whether TFIIS.h is a direct transcriptional target of p53, we screened the upstream sequences of the TFIIS.h-coding gene and identified two putative p53 response elements (p53REs) in the promoter region using p53MH software. We then inserted these two p53REs into a pGL3 enhancer-luciferase reporter plasmid and carried out luciferase assays to test if p53 could directly bind to these two p53REs. As shown in Fig. 2B, p53 promoted luciferase activity driven by p53RE2, but not p53RE1, indicating that p53 directly binds to the p53RE2 DNA sequence located at the promoter region of the TFIIS.h gene. This result was further confirmed by a chromatin immunoprecipitation analysis (ChIP) (Fig. 2C), indicating that endogenous p53 can directly bind to the p53RE2 DNA sequence of the
TFIIS.h promoter region upon activation. Taken together with the results of Fig. 1, these results demonstrate that TFIIS.h is a direct transcriptional target of p53.

**Knocking down TFIIS.h impairs the induction of bax, but not p21, by p53 activation.** Since TFIIS.h has been reported to be required for Pol II to pass through transcription arresting sites, we speculated that TFIIS.h might be involved in the transcription of some p53 target genes and thus function to selectively induce their expression associated with different cellular pathways. To test this idea, we knocked down TFIIS.h and checked the expression of several p53 target genes associated with various cellular functions in H1299 cells that were transfected with different amounts of the GFP-p53 plasmid. Surprisingly, while the expression of most tested p53 target genes, including cell cycle-associated p21, autophagy-associated DRAM1, and survival-associated TIGAR, was not affected by depleting TFIIS.h, knocking down TFIIS.h dramatically impaired the induction of apoptosis-associated bax by p53 (Figs S1 and 3A). To further confirm that TFIIS.h is required for the induction of bax by endogenous p53 in response to DNA damage stress, we treated HCT116 cells with doxorubicin, a chemotherapeutic drug that causes DNA damage, and then examined the effect of TFIIS.h knockdown on bax expression. As expected, induction of bax by endogenous p53 was impaired significantly by ablating TFIIS.h, while p21 expression was not affected (Fig. 3B). These results suggest that TFIIS.h might be involved in regulation of transcription efficiency of bax.

Next, we tested whether p53-mediated transcription of bax is specifically regulated by flag-TFIIS.h, but not flag-TFIIS.l, by carrying out RT-q-PCR and WB after introduction of their expression plasmids with or without p53 into H1299 cells. As shown in Fig. 4A, while ectopic p53 induced the expression of bax, this induction was quite moderate, which was consistent with literature. Remarkably, when titrating the TFIIS.h expression plasmid with different amounts of the p53 expression vector, this elongation factor drastically boosted the expression of bax in a dose-dependent fashion (Fig. 4A). By contrast, TFIIS.l was unable to do so (Fig. 4A). Consistently, the induction of bax protein levels by ectopic p53 was more dramatic in cells with high level of ectopic TFIIS.h than that in cells without overexpression of TFIIS.h (Fig. 4B). Again, the p53-induced expression of p21 was not elevated by ectopic TFIIS.h (Fig. 4B). These results demonstrate that TFIIS.h can promote transcription efficiency of bax, but not p21, in response to p53 and implicate that this regulation might be via transcriptional elongation.

**TFIIS.h forms a complex with bax mRNA and DNA in cells.** It has been shown that TFIIS.h is recruited to transcription arresting sites and forms a complex with RNA pol II to help stalled RNA pol II pass through arrested sites. Therefore, we assumed that TFIIS.h should be in the same complex of RNA pol II, bax mRNA, and DNA, if bax is a target gene of TFIIS.h. To test this idea, we transfected H1299 cells with or without flag-TFIIS.h and carried out RNA-protein complex immunoprecipitation using the anti-flag antibody. As expected, TFIIS.h only pulled down bax, but not p21, mRNA (Fig. 4C), confirming that TFIIS.h specifically regulates transcription elongation of the former, but not the latter.

Next, we speculated that TFIIS.h should be enriched at the upstream of arresting site(s) located on the bax gene. To test this idea, we transfected H1299 cells with flag-TFIIS.h or pcDNA3 as a control and performed ChIP assays with various primers designed for different sites of bax DNA, including −2073, −55, +5945, +9887, and +11623 from its transcription initiation site, which were used for identifying the binding sites of TFIIS.h on the bax gene. As shown in Fig. 4D, flag-TFIIS.h pulled down endogenous bax DNA, suggesting that TFIIS.h is indeed recruited to the bax gene during transcription. Interestingly, more DNAs localized in the upstream of +5945 site of the bax gene were pulled down by flag-TFIIS.h than that in the downstream sites, suggesting that the transcription arresting site of the bax gene is localized between +5945 and +9887 from initiation site. These data further confirm that TFIIS.h is recruited to the bax gene and function to promote the transcription efficiency of this gene. Notably, when we checked human cancer samples available from cBioportal, we found that TFIIS.h and bax display significant tendency towards co-occurrence in expression alteration (elevation or reduction) (Fig. S2).
TFIIS.h promotes cell death and is downregulated in human gastric cancer tissues. As bax had been shown to accelerate programmed cell death, we then sought to determine whether TFIIS.h could facilitate cancer cell growth inhibition or cell death. H1299 cells transfected with Flag-TFIIS.h or pCDNA3 were harvested and subjected to colony formation and cell viability assays. As shown in Fig. 5A, overexpression of TFIIS.h dramatically suppressed colony formation of H1299 cells, suggesting that TFIIS.h inhibits cell growth, which is in line with literature showing that bax induces apoptosis. We then tested whether the inhibitory effect of TFIIS.h on colony formation is bax-dependent or not. Interestingly, depletion of endogenous bax by siRNAs rescued the suppression of colony formation by ectopic TFIIS.h (Fig. 5A). This result indicates that TFIIS.h functions to inhibit cancer cell growth by regulating bax expression. To further confirm this result, we performed cell viability assays using three different cell lines, H1299, HCT116, and U2OS cells. As expected, overexpression of TFIIS.h inhibited cell viability of all the tested cells (Fig. 5B). Consistently with the results from colony formation assays, the inhibitory effect of TFIIS.h on cell viability was impaired by knocking down bax, as shown in Fig. 5B, indicating that TFIIS.h promotes cell death at least partially in a bax-dependent fashion. We noticed that knocking down bax did not completely abrogate the inhibitory effects of TFIIS.h on cell viability, which is probably due to 1) bax siRNA did not remove all the bax expression in our experiments, and 2) TFIIS.h might also regulate cell viability via bax-independent pathways. Next, we examined whether depletion of endogenous TFIIS.h could suppress cell death induced by p53 activation. To test this, we knocked down TFIIS.h in HCT116 cells treated with or without doxorubicin and carried out cell cycle analysis. Interestingly, in line with the above findings, ablation of TFIIS.h significantly impaired cell death induced by doxorubicin (Fig. 5C), suggesting that TFIIS.h is required for apoptosis induced by p53 activation. We then examined whether TFIIS.h knockdown could affect p53-induced cell cycle arrest by FACS analysis. However, we did not see significant G1 arrest in HCT116 cells treated with Dox. Therefore, we examined the effect of siTFIIS.h on G1 arrest in H1299 cells with ectopic p53. As expected, depletion of TFIIS.h had no effect on G1 arrest induced by ectopic p53 (Fig. 5D), which is in line with our finding that TFIIS.h does not regulate the expression of p21, a cell-cycle associated target of p53. These results suggest that TFIIS.h functions as a tumor suppressor during cancer development, and implies that TFIIS.h might be downregulated in human cancers. We then analyzed TFIIS.h mRNA levels in 30 paired human gastric tumor and normal tissues, and found that TFIIS.h is significantly downregulated in cancer tissues compared with normal tissues.
further confirming that TFIIIS.h might act as a tumor suppressor in human cancers (Fig. 5E). In summary, these results demonstrate that TFIIIS.h is important for bax-mediated apoptosis in response to p53 activation and may play a role as a tumor suppressor by regulating p53-dependent bax expression.

**Discussion**

It has been known that p53 activates the expression of numerous transcriptional target genes that encode proteins critical for regulation of various cellular pathways or processes in response to different stresses\(^1\text{–}^8\). Often these target genes are expressed to different degrees and at different time points upon p53 activation. Although comprehensive studies have proposed that posttranslational modifications of p53 and promoter strength of its target genes might be involved in the selection of p53 target genes and the regulation of their expression\(^10,11,15\text{–}22\), little is known about whether selection of p53 target genes is regulated at a transcriptional elongation level. In this study, we unraveled TFIIIS.h, a transcription elongation factor that is required for pol II to pass through arresting sites\(^29\), as a novel transcription target of p53 (Figs 1 and 2). Surprisingly, we found that TFIIIS.h binds to bax DNA and is required for bax, but not p21, induction by p53 (Figs 3b–5 and S1). Also, we found that TFIIIS.h promotes cancer cell death in a bax-dependent fashion (Fig. 5a–d). Furthermore, TFIIIS.h was downregulated in human gastric cancers, suggesting that it is a tumor suppressor (Fig. 5e). Based on these findings, we propose that TFIIIS.h is involved in selection of some p53 target genes, such as bax as shown here, at the transcription elongation level.

Although p53 target genes have similar RE sequences, the kinetics of their transcription vary dramatically\(^10,11,15\text{–}19,49\text{–}52\). Often, p53 rapidly induces genes whose proteins are important for controlling the cell cycle, but its action on the expression of apoptosis-related genes is delayed\(^52\). Although the biological reason for these
differential actions of p53 on gene expression are generally understood, i.e., p53 might need to first rescue less genomically damaged cells through a growth arrest mechanism prior to killing them via apoptosis, the mechanisms underlying the delayed transcription of apoptotic genes by p53 remain largely unknown. As depletion of TFIIS causes transcription elongation arrest at sites with specific DNA sequences, it is possible that genes with elongation arrest sites might need another layer of regulation to facilitate their expression. Here, we propose that TFIIS.h might facilitate the selection of p53 targets at the transcription elongation level in response to different stresses by proposing the following possible mechanisms (Fig. 5F): Phase 1: upon moderate DNA damage or ribosomal stress, when cell cycle arrest is required for the recovery of cells, p53 is activated by posttranslational modifications, and thus induces the transcriptions of some cell cycle-associated genes, such as p21. However, the transcription of apoptosis-associated genes, such as bax, is stalled at specific sites to avoid unnecessary apoptosis in cells. Phase 2: in response to continuous and severe stresses, when apoptosis is required to avoid tumorigenesis, TFIIS.h is accumulated by continuously activating p53 and acts to rescue the transcription elongation arrest of apoptosis-associated genes, such as bax.

Figure 5. TFIIS.h promotes cell death without affecting cell cycle arrest. (A,B) Overexpression of TFIIS.h inhibits cancer cell growth in a bax-dependent manner. H1299, U2OS, or HCT116 cells transfected with indicated plasmids and/or siRNAs were subjected to colony formation assay (A) and cell viability assay (B). Data are presented as means ± S.D., n = 3. *p < 0.05. Δp < 0.05 as compared to pcDNA control. (C,D) TFIIS.h knockdown suppresses cell death, but not cell cycle arrest, induced by p53 activation. TFIIS.h knockdown impaired Dox-induced cell death. (C) HCT116 cells with indicated treatments were harvested (72 hours) for FACS analysis to determine sub-G1 cells. P values were determined using an unpaired Student’s t test. *p < 0.05. Data are presented as means ± S.D., n = 4. (D) TFIIS.h knockdown did not affect p53-induced G1 arrest. H1299 cells transfected with indicated plasmids and harvested (24 hours) for FACS analysis. (E) TFIIS.h is downregulated in human gastric cancers. Next generation sequencing datasets from The Cancer Genome Atlas (TCGA) initiative were downloaded from the Cancer Genomics Hub (CGHub; https://cghub.ucsc.edu) and RNA-seq datasets from 30 paired gastric adenocarcinomas and normal tissue are included for analysis. *p < 0.05. Data are presented as means ± S.D. TPM: transcripts per million. (F) Schematic of possible selection of p53 targets in response to various stresses. Phase 1: in response to moderate damages, when cell cycle arrest is required for the recovery of cells, p53 is activated by posttranslational modifications, and thus induces the transcriptions of some cell cycle-associated genes, such as p21. However, the transcription of apoptosis-associated genes, such as bax, is arrested at specific sites to avoid unnecessary apoptosis in cells. Phase 2: in response to continuous and severe stresses, when apoptosis is required to avoid tumorigenesis, TFIIS.h is accumulated by continuously activating of p53 and acts to rescue the transcription elongation arrest of apoptosis-associated genes, such as bax.
could unexpectedly induce apoptosis in cancer cells\(^\text{28}\). However, it is still largely unknown if TFIIS.h has a specific pool of target genes, which could be addressed in our future studies.

In this study, we show that TFIIS.h promotes transcription elongation efficiency of bax gene. As bax is a transcriptional target of p53, we speculate that TFIIS.h should specifically induce cell death in cells with active p53 functions. However, we did observe that ectopic TFIIS.h could suppress growth of H1299 cells, a p53 null cell line, in cell viability assays, although the suppression of cell growth in H1299 cells (11% suppression) was not as dramatic as those in HCT116 and U2OS cells (33% and 52% suppression), both of which express wild type p53. This could be due to the existence of other transcriptional factors controlling bax expression in H1299 cells, or other apoptosis-associated targets of TFIIS.h. Our future study identifying more specific targets of TFIIS.h by microarray analysis of cells with ectopic TFIIS.h or with depletion of TFIIS.h could address this interesting question and lead to more findings of the regulation of gene expression at the transcriptional elongation level.

In summary, our findings reveal a novel mechanism of how TFIIS.h could exert its tumor suppressive functions in facilitating p53 induction of bax. Our study not only unravels TFIIS.h as another novel bona fide target of p53, but also provides new insights into better understanding its precise regulation of the kinetics of transcription of p53 target genes associated with different cellular functions. In addition, this study also offers proof-of-concept evidence for selectively inducing apoptosis by TFIIS.h upon p53 activation, providing a potentially novel target for future identification and development of new therapies for chemo-resistant cancers.

**Experimental Procedures**

**Cell lines, plasmids, and antibodies.** Human HCT116 p53\(^{+/−}\) and HCT116 p53\(^{−/−}\) cells were generous gifts from Dr. Bert Vogelstein at the Johns Hopkins Medical Institutes. U2OS and H1299 cells were purchased from American Type Culture Collection (ATCC). All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin and 0.1 mg/ml streptomycin at 37°C in a 5% CO\(_2\) humidified atmosphere. p53 expression plasmids were described previously\(^\text{39-58}\). TFIIS.h p53 RE1 and p53 RE2 were amplified and inserted into the pGL3 Enhancer Reporter vector. TFIIS.h and TFIIS.l expression plasmids were amplified from HCT116 cells and inserted into pCDNA3.Flag vector. Anti-Flag (Sigma), anti-p53 (DO-1, Santa Cruz Biotechnology), anti-actin (Sigma), anti-p21 (CP74, LifeSpan BioSciences, Inc.), anti-TFIIS.h (TCE51551, Santa Cruz Biotechnology), anti-bax (N-20, Santa Cruz Biotechnology) were commercially purchased.

**RNA preparation and microarray analysis.** As described previously\(^\text{39}\), briefly, HCT116\(^{p53^{+/−}}\) or HCT116\(^{p53^{−/−}}\) cells were treated with 4 μM INZ and harvested at 18 hours post treatment. Cells were then homogenized in TriZol reagents. Three replicates were included for each sample. Total RNA was extracted by following the manufacturer’s standard instructions (Invitrogen). RNA quality was confirmed by agarose electrophoresis and only those samples showing no degradation (ratios approaching 2:1 for the 28S and 18S bands) were sent to Arraystar Inc. (Rockville, MD), where the microarray analysis was performed on Roche/Nimblegen platform in a 12 × 135 k format. Our microarray data are deposited in GEO with accession number GSE77669.

**Transient transfection and WB analyses.** As described previously\(^\text{39,60}\), briefly, cells were transfected with indicated plasmids as shown in each figure by using TransFectin (Bio-Rad), following the company’s instruction. Unless specifically mentioned, forty eight hrs post transfection, cells were harvested and lysed in lysis buffer. The total protein concentration for each sample was determined and equal amount of total proteins were then subjected to SDS-PAGE, followed by WB analysis.

**Reverse transcriptase-polymerase chain reaction and quantitative real-time PCR analysis.** RT and Q-PCR for mRNAs were done by using the methods described previously\(^\text{42,55}\). Briefly, quantitative real-time PCR was performed on an ABI 7300 real-time PCR system (Applied Biosystems) using SYBR Green Mix (Applied Biosystems). Relative gene expression was calculated using the ΔCT method, following the manufacturer’s standard instructions (Invitrogen). RNA quality was confirmed by agarose electrophoresis and only those samples showing no degradation (ratios approaching 2:1 for the 28S and 18S bands) were sent to Arraystar Inc. (Rockville, MD), where the microarray analysis was performed on Roche/Nimblegen platform in a 12 × 135 k format. Our microarray data are deposited in GEO with accession number GSE77669.

**Luciferase reporter assays.** Cells were transfected with pGL3-TFIIS.h p53RE1 or GL3-TFIIS.h p53RE2 and indicated plasmids (total plasmid DNA 1 µg/well) as indicated in figures. Luciferase activity was determined and normalized by a factor of β-gal activity in the same assay as described previously\(^\text{42,63}\).

**Chromatin immunoprecipitation (ChIP)-PCR.** ChIP analysis was performed as described previously\(^\text{42,63}\) using anti-p53 (DO-1) for endogenous p53 and anti-flag for overexpressed flag-TFIIS.h. Immunoprecipitated DNA fragments were analyzed by real-time PCR amplification using primers for indicated genes. The control primers targeting other region in the genome are as follows: 5′-AACGGTGTGTGCTTGCC-3′, 5′-TCTGGTCCTCACCTAAAACGCC-3′.

**Cell viability assay.** Cell viability assay was carried out as described previously. Briefly, cell viability was evaluated by cell counting kit (Dojindo Molecular Technologies Inc., Gaithersburg, Maryland). Cells treated as indicated were seeded onto 96-well micro plates at a density of 2 × 10\(^4\) cells per well. The cells were incubated WST-8 at a final concentration of 10% to each well and incubate for 3 h. Optical density (OD) was measured using a micro plate reader (Molecular Device, SpectraMax M5\(^\text{®}\)) at 450 nm. Cell viability was calculated as a percentage of viable cells in drug-treated group versus untreated control by following equation.

\[
\text{Cell viability (％)} = \frac{[\text{OD (Drug)} - \text{OD (Blank)}]}{[\text{OD (Control)} - \text{OD (Blank)}]} \times 100
\]
Ribonucleoprotein immunoprecipitation (RNP IP) assay. RNP-IP assay was performed as described previously using the anti-FLAG antibody for ectopic proteins. Immunoprecipitated RNAs were extracted and analyzed by real-time PCR amplification using primers for indicated genes.

Knockdown of endogenous mRNAs. siRNA for TFIIS.h was purchased from Santa Cruz Biotechnology. Transfection of siRNAs were performed the same as that of normal siRNA as described previously by using siLentFect™ Lipid (Bio-Rad), following the manufacturer’s protocol.

Human gastric tumor and normal tissue RNA-seq datasets. Next generation sequencing datasets from The Cancer Genome Atlas (TCGA) initiative were downloaded from the Cancer Genomics Hub (CGHub; https://cghub.ucsc.edu) and included RNA-seq datasets from normal gastric tissue (n = 33) and gastric adenocarcinomas (n = 285). 30 patients with paired normal and tumor tissues available were used for TFIIS.h expression analysis. Human gene expression was quantified using RSEM (RNA-seq by Expectation-Maximization) (35) (using the hg19 reference genome, default parameters).

References
1. Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62, doi: 10.1038/nature14344 (2015).
2. Sakaguchi, K. et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes & development 12, 2831–2841 (1998).
3. Leonova, K. I. et al. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proceedings of the National Academy of Sciences of the United States of America 110, E89–98, doi: 10.1073/pnas.1216922110 (2013).
4. Lowe, S. W. Activation of p53 by oncogenes. Endocrine-related cancer 6, 45–48 (1999).
5. Zhang, Y. & Lu, H. Signalling to p53: ribosomal proteins find their way. Cancer cell 16, 369–377, doi: 10.1016/j.cccr.2009.09.024 (2009).
6. Zhou, X., Liao, J. M., Liao, W. J. & Lu, H. Scission of the p53-MDM2 Loop by Ribosomal Proteins. Genes Cancer 3, 298–310, doi: 10.1177/1947601912455200 (2012).
7. Boren, J. & Brindle, K. M. Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell death and differentiation 19, 1561–1570, doi: 10.1038/cdd.2012.34 (2012).
8. Serneus, A. & Michiels, G. Reciprocal influence of the p53 and the hypoxic pathways. Cell death & disease 2, e164, doi: 10.1038/cddis.2011.48 (2011).
9. Krummel, K. A., Lee, C. J., Toledo, F. & Wahl, G. M. The C-terminal lysines fine-tune P3 stress responses in a mouse model but are not required for stability control or transactivation. Proceedings of the National Academy of Sciences of the United States of America 102, 10188–10193, doi: 10.1073/pnas.0503608102 (2005).
10. Kruse, J. P. & Gu, W. Modes of p53 regulation. Cell 137, 609–622, doi: 10.1016/j.cell.2009.04.050 (2009).
11. Loewer, A., Batchelor, E., Gagli, G. & Lahav, G. Basal dynamics of p53 reveal transcriptionally attenuated pulsations in cycling cells. Cell 142, 89–100, doi: 10.1016/j.cell.2010.05.031 (2010).
12. Barboza, J. A., Iwakuma, T., Terzian, T., El-Naggar, A. K. & Lozano, G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Molecular cancer research: MCR 6, 947–954, doi: 10.1158/1541-7786.MCR-07-2079 (2008).
13. Tang, Y., Luo, J., Zhang, W. & Gu, W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Molecular cell 24, 827–839, doi: 10.1016/j.molcel.2006.11.021 (2006).
14. Samuels-Lev, Y. et al. ASPP proteins specifically stimulate the apoptotic function of p53. Molecular cell 8, 781–794 (2001).
15. Lauberth, S. M. et al. H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell 152, 1021–1036, doi: 10.1016/j.cell.2013.01.052 (2013).
16. Tang, Y., Zhao, W., Chen, S., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612–626, doi: 10.1016/j.cell.2008.03.025 (2008).
17. Brooks, C. L. & Gu, W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Current opinion in cell biology 15, 164–171 (2003).
18. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595–606 (1997).
19. Knights, C. D. et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. The journal of cell biology 173, 533–544, doi: 10.1083/jcb.200512059 (2006).
20. Luo, J., Su, E., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408, 377–381, doi: 10.1038/35042612 (2000).
21. Sykes, S. M. et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Molecular cell 24, 841–851, doi: 10.1016/j.molcel.2006.11.026 (2006).
22. Wind, M. & Reines, D. Transcription elongation factor SII. BioEssays: news and reviews in molecular, cellular and developmental biology 22, 327–336, doi: 10.1002/scbi.12151-1878(200403224<327::AID-BIEME>3.0.CO;2-I (2000).
23. Sethi, L. A., Sigurdsson, S. & Svejstrup, J. Q. Transcript Elongation by RNA Polymerase II. Annual review of biochemistry 79, 271–293, doi: 10.1146/annurev.biochem.78.062807.091425 (2010).
24. Labhart, P. & Morgan, G. T. Identification of novel genes encoding transcription elongation factor TFIIS (TCEA) in vertebrates: conservation of three distinct TFIIS isoforms in frog, mouse, and human. Genomics 52, 278–288, doi: 10.1016/j.geno.1998.5449 (1998).
25. Ito, T. et al. Transcription elongation factor S-II is required for definitive hematopoiesis. Molecular and cellular biology 26, 1319–13203, doi: 10.1128/MCB.26.8.1319-13203.2006 (2006).
26. Bolognesi, R., Fenoglio, C., Catapano, A., Beretta, A. Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis. BMC cancer 8, 135, doi: 10.1186/1471-2407-8-133 (2008).
27. Cha, Y., Kim, D. K., Hyun, J., Kim, S. J. & Park, K. S. TCEA3 binds to TGF-beta receptor 1 and induces Smad-independent, INK-dependent apoptosis in ovarian cancer cells. Cellular signalling 25, 1245–1251, doi: 10.1016/j.cellsig.2013.01.016 (2013).
28. Bengal, E., Flores, O., Krauskopf, A., Reinberg, D. & Aloni, Y. Role of the mammalian transcription factors IIe, IIb, and IIx during elongation by RNA polymerase II. Molecular and cellular biology 11, 1195–1206 (1991).
29. Mavragani, E., Herrero, E., et al. One step back before moving forward: regulation of transcription elongation by arrest and backtracking. FEBS letters 586, 2820–2825, doi: 10.1016/j.febslet.2012.07.030 (2012).
30. Kash, S. F., Innis, J. W., Jackson, A. U. & Kellem, R. E. Functional analysis of a stable transcription arrest site in the first intron of the murine adenine deaminase gene. Molecular and cellular biology 13, 2718–2729 (1993).
Author Contributions
H.L. and J.L. designed experiments and wrote the main manuscript text. J.L. prepared all the data except those presented in Figure 5A and B.C., S.X.Z. and X.Z. prepared some plasmids and provided technical supports. J.D. and J.X. prepared the data shown in Figure 5A and M.S. and E.F. prepared raw data for Figure 5E. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Liao, J.-M. et al. TFIIS.h, a new target of p53, regulates transcription efficiency of pro-apoptotic bax gene. Sci. Rep. 6, 23542; doi: 10.1038/srep23542 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/